MALIGNANT HYPERTHERMIA TREATMENT WITH AGILUS

(dantrolene sodium hemiheptahydrate)[1]

AGILUS™ DANTROLENE SODIUM HEMIHEPTAHYDRATE

In combination with adequate support measures, AGILUS® is indicated for the treatment of malignant hyperthermia in adults and children of all ages.[1]

AGILUS® should be administered rapidly by intravenous injection at an **initial dose of 2.5 mg/kg body weight** for both adult and paediatric patients.[1]

1

Calculate
the number of vials of AGILUS® required (see table below). Each vial contains 120mg of dantrolene.

2

Reconstitute
each vial with 20 mL of water for injections and shake for approximately 1 minute, before inspecting for particulates. Further shaking may be necessary.

3

Administer
reconstituted AGILUS® without mixing with other solutions or giving via the same venous access.

4

Apply
other supportive measures alongside AGILUS®.

Dosing examples by body weight to achieve a loading dose of 2.5 mg/kg for both adults and children[1]

Number of vials to be prepared[a]	Body weight range	Example dosing recommendation		
		Body weight	Dose to be administered	Volume to be administered[a]
1	Up to 48 kg	3 kg	7.5 mg	1.4 mL
		6 kg	15 mg	2.8 mL
		12 kg	30 mg	5.6 mL
		24 kg	60 mg	11.3 mL
		48 kg	120 mg	22.6 mL
2	From 49 kg to 96 kg	72 kg	180 mg	33.9 mL
		96 kg	240 mg	45.2 mL
3	From 97 kg	120 kg	300 mg	56.5 mL
		144 kg[b]	300 mg[b]	56.5 mL

a.Total volume of one reconstituted vial is 22.6mL
b. For all body weights , the initial dose and any repeat doses should not exceed 300 mg, equivalent to 2.5 vials

As long as the main clinical symptoms persist, bolus injection of 2.5 mg/kg should be repeated every **10 minutes** *until physiological and metabolic abnormalities improve.[1] If a cumulative dose of 10 mg/kg or above is considered, the diagnosis of malignant hyperthermia should be re-examined.[1]*

Click or scan to view Prescribing information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Norgine Pharmaceuticals Ltd on: Tel: +44 (0)1895 826 606 Email: medinfo@norgine.com

NORGINE

Note: AGILUS® is a skeletal muscle relaxant. The most commonly reported adverse event is skeletal muscle weakness.

1. AGILUS®. Summary of product characteristics

To request further copies of this material, please contact: ukisupport@norgine.com **Job code:** UK-EC-AGI-2400039 **Date of preparation:** December 2024